![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pharmacokinetics of Dolutegravir in Subjects With Moderate Hepatic Impairment
|
|
|
Reported by Jules Levin
CROI 2012 March 5-8 Seattle WA
Ivy Song, Julie Borland, Paul Savina, Shuguang Chen, Parul Patel, Toshihiro Wajima, Amanda Peppercorn, Stephen Piscitelli
GlaxoSmithKline, Research Triangle Park, NC, United States, and Shionogi & Co., Ltd., Osaka, Japan
![CROI1.gif](../images/031912/031912-3/CROI1.gif)
![CROI2.gif](../images/031912/031912-3/CROI2.gif)
![CROI3.gif](../images/031912/031912-3/CROI3.gif)
![CROI4.gif](../images/031912/031912-3/CROI4.gif)
![CROI5.gif](../images/031912/031912-3/CROI5.gif)
![CROI6.gif](../images/031912/031912-3/CROI6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|